Expanding Horizons: Liquid Biopsy’s Market Potential in 2023 to 2033

The global liquid biopsy market value is expected to rise from US$ 1,538.3 million in 2023 to US$ 10,938.6 million by 2033. This estimated growth is expected to be driven by a remarkable CAGR of 21.7% in the global liquid biopsy market over the next decade.

Several biomedical research centers and the pharmaceutical industry aim to enhance treatments’ efficacy and detect a pathological condition at its early stage. Since clinical genetic analyses and cancer diagnosis require sampling via tumor biopsy, the increasing cases of cancer across the globe are creating an optimistic outlook for the sales of liquid biopsy over the next decade.

Request A Report Sample To Gain Comprehensive Insights! https://www.futuremarketinsights.com/reports/sample/rep-gb-1396

Presently, tumor tissue is a gold standard source for cancer characterization and diagnosis. Key players are working on the current barriers associated with its usage to extend its applicability in the future. Several studies have also come to light that discover the potential of liquid biopsy approaches to determine the genetic profiles of cancer in cancer patients. The studies also consider the responses to monitor treatment and latch on to the inception of therapy resistance. In recent years, the demand for personalized treatment options has propelled the use of liquid biopsy.

The use of liquid biopsy is also rising due to its availability in numerous labs, even in emerging economies, and its affordability. For instance, liquid biopsy tests can be found in several labs in India. 4baseCare is one of the leading companies that offer affordable and advanced comprehensive genetic testing solutions in the country.